Oral phosphodiesterase 4B inhibitor shows promise for preventing lung function decline in IPF - Healio

5/15/2022 12:00:00 AM2 years 11 months ago

SAN FRANCISCO — Treatment with an oral preferential phosphodiesterase 4B inhibitor prevented lung function decline among patients with idiopathic pulmonary fibrosis, regardless of background antifibrotic therapy use.The phase 2 trial enrolled 147 adults…

Source/Disclosures Source: Richeldi L, et al. The New England Journal of Medicine and JAMA Discussion on the Edge: Reports of Recently Published Pulmonary Research. Presented at: American Thoracic … [+4074 chars]

full article...

Oral phosphodiesterase 4B inhibitor shows promise for preventing lung function decline in IPF - Healio

SAN FRANCISCO &mdash; Treatment with an oral preferential phosphodiesterase 4B inhibitor prevented lung function decline among patients with idiopathic pulmonary fibrosis, regardless of background antifibrotic therapy use.The phase 2 trial enrolled 147 adults…

SAN FRANCISCO — Treatment with an oral preferential phosphodiesterase 4B inhibitor prevented lung function decline among patients with idiopathic pulmonary fibrosis, regardless of background antifibrotic therapy use.The phase 2 trial enrolled 147 adults…